Reply to 'Personalized treatment of immune-related adverse events - balance is required'
- PMID: 32546734
- DOI: 10.1038/s41571-020-0401-3
Reply to 'Personalized treatment of immune-related adverse events - balance is required'
Comment on
-
Moving towards personalized treatments of immune-related adverse events.Nat Rev Clin Oncol. 2020 Aug;17(8):504-515. doi: 10.1038/s41571-020-0352-8. Epub 2020 Apr 3. Nat Rev Clin Oncol. 2020. PMID: 32246128 Review.
-
Personalized treatment of immune-related adverse events - balance is required.Nat Rev Clin Oncol. 2020 Aug;17(8):517. doi: 10.1038/s41571-020-0400-4. Nat Rev Clin Oncol. 2020. PMID: 32546733 No abstract available.
References
-
- Esfahani, K. et al. Moving towards personalized treatments of immune-related adverse events. Nat. Rev. Clin. Oncol. https://doi.org/10.1038/s41571-020-0352-8 (2020). - DOI - PubMed
-
- Martins, F. and Obeid, M. Personalized treatment of immune-related adverse events — balance is required. Nat. Rev. Clin. Oncol. https://doi.org/10.1038/s41571-020-0400-4 (2020). - DOI - PubMed
-
- Martins, F. et al. New therapeutic perspectives to manage refractory immune checkpoint-related toxicities. Lancet Oncol. 20, e54–e64 (2019). - DOI
-
- Esfahani, K. et al. Alemtuzumab for immune-related myocarditis due to PD-1 therapy. N. Engl. J. Med. 380, 2375–2376 (2019). - DOI
-
- Esfahani, K. et al. Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation. Nat. Commun. 10, 4712 (2019). - DOI
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
